The estimated Net Worth of Blaise Coleman is at least $3.72 Milion dollars as of 29 March 2022. Mr Coleman owns over 125,573 units of Endo International plc stock worth over $126,463 and over the last 8 years he sold ENDP stock worth over $0. In addition, he makes $3,595,337 as Pres i CEO & Director at Endo International plc.
Sign up
Mr Coleman ENDP stock SEC Form 4 insiders trading
Mr has made over 4 trades of the Endo International plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 125,573 units of ENDP stock worth $36,743 on 29 March 2022.
The largest trade he's ever made was exercising 125,573 units of Endo International plc stock on 29 March 2022 worth over $36,743. On average, Mr trades about 12,199 units every 65 days since 2017. As of 29 March 2022 he still owns at least 432,203 units of Endo International plc stock.
You can see the complete history of Mr Coleman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Blaise Coleman biography
Blaise Coleman is the Pres, CEO & Director at Endo International plc.
What is the salary of Mr Coleman?
As the Pres i CEO & Director of Endo International plc, the total compensation of Mr Coleman at Endo International plc is $3,595,337. There are 2 executives at Endo International plc getting paid more, with Paul Campanelli having the highest compensation of $13,118,300.
How old is Mr Coleman?
Mr Coleman is 47, he's been the Pres i CEO & Director of Endo International plc since . There are 13 older and 2 younger executives at Endo International plc. The oldest executive at Endo International plc is Michael Hyatt, 74, who is the Independent Director.
What's Mr Coleman's mailing address?
Blaise's mailing address filed with the SEC is C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN, L2, .
Insiders trading at Endo International plc
Over the last 11 years, insiders at Endo International plc have traded over $3,455,441 worth of Endo International plc stock and bought 152,347 units worth $3,901,804 . The most active insiders traders include Silva Rajiv De, Paul Campanelli oraz Shane Cooke. On average, Endo International plc executives and independent directors trade stock every 36 days with the average trade being worth of $12,163. The most recent stock trade was executed by Patrick A Barry on 29 March 2022, trading 59,298 units of ENDP stock currently worth $17,351.
What does Endo International plc do?
Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.
What does Endo International plc's logo look like?
Complete history of Mr Coleman stock trades at Endo International plc
Endo International plc executives and stock owners
Endo International plc executives and other stock owners filed with the SEC include:
-
Paul Campanelli,
Chairman of the Board -
Terrance Coughlin,
Chief Operating Officer, Executive Vice President -
Blaise Coleman,
Pres, CEO & Director -
Blaise Coleman,
President, Chief Executive Officer, Director -
Matthew Maletta,
Executive Vice President, Chief Legal Officer -
Patrick Barry,
Executive Vice President and Chief Commercial Officer, U.S. Branded Business -
Patrick A. Barry,
Exec. VP & Pres of Global Commercial Operations -
Mark T. Bradley,
Exec. VP & CFO -
Roger Kimmel,
Senior Independent Director -
Shane Cooke,
Independent Director -
William Montague,
Independent Director -
Nancy Hutson,
Independent Director -
Michael Hyatt,
Independent Director -
M. Christine Smith,
Independent Director -
Mark Barberio,
Independent Director -
Jack Boyle,
Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller -
Rahul Garella,
Executive Vice President, International Pharmaceuticals -
Domenico Ciarico,
Executive Vice President and Chief Commercial Officer, Sterile and Generics -
Joseph A. Barbarite,
Exec. VP of Global Quality and Compliance -
Tracy Basso,
Chief HR Officer -
Susan Williamson,
Sr. VP & Chief Compliance Officer -
Laure E. Park,
Sr. VP of Investor Relations & Corp. Affairs -
Ruth Thorpe,
Sr. VP of Information Technology & Chief Information Officer -
Robert Polke,
Exec. VP & Global Head of Operations -
Arthur J Higgins,
Director -
Douglas S Ingram,
Director -
Hemanth Jacob Varghese,
Pres. International Pharma -
Suketu Upadhyay,
EVP, Chief Financial Officer -
Antonio R Pera,
President, Par Pharmaceutical -
Joseph Ciaffoni,
President, U.S. Branded Pharma -
Carrie Ann Nichol,
SVP, Controller & CAO -
Mark T. Bradley,
EVP, Chief Financial Officer -
Frank B. Raciti,
VP, Controller and CAO -
Daniel Rudio,
Vice President, Controller -
Sharad Mansukani,
Director -
William Spengler,
Director -
Silva Rajiv De,
President & CEO -
John Delucca,
Director -
Brian Lortie,
President Branded Pharma -
Susan Hall,
EVP, CSO, Global Head of R&D -
Caroline B Manogue,
Exec. V.P., CLO & Secy -
Camille Farhat,
President, AMS, Inc. -
Ivan P. Gergel,
EVP, R&D and CSO -
Donald W De Golyer,
Chief Operating Officer,Pharma -
Mary Christine Smith,
Director -
George Apostol,
EVP, Global R&D -
Jennifer M Chao,
Director -
James Patrick Tursi,
Executive VP, Global R&D